Pcn219 What Is Worth Knowing at Early Development? Value of Information Analysis Using an Indication-Agnostic Web-Based Platform: A Case Study

Abstract

Objectives: Hematological cancers are amongst the diseases that pose the highest burden on patients in terms of reduced quality of life, frequent relapses and reductions in life expectancy. For multiple myeloma (MM), lenalidomide-based therapy options significantly prolong progression-free survival (PFS) and overall survival (OS). Longer PFS, in turn, yields economic and societal gains as it enables patients to pursue their every-day activities and participate in the labor market. The purpose of this study was twofold: (1) To quantify the health benefits of using lenalidomide in the treatment of multiple myeloma and (2) to measure the socio-economic benefits that are associated with this improved health. We considered, retrospectively, the benefits of lenalidomide since its introduction in 2007 as well as its prospective effects up to the year 2030. Methods: We built an open cohort dynamic population model. The gains in PFS associated with the use of lenalidomide were projected to the overall MM patient population in Germany. Using German administrative employment data and information from time use surveys, we translated these PFS advantages into productivity gains. Gains in OS were valued with the statistical value of a life year (VSLY). Cost calculations distinguished between costs for lenalidomide and additional treatment costs in combination therapies. Results: Through 2030, about 64 thousand progression-free years can be gained by utilizing lenalidomide as compared to the respective best alternative therapy. Including the VSLY, the societal impact amounts to about EUR 21.0 billion. Total additional costs for the treatment of MM patients with lenalidomide-based regimens sum up to EUR 12.8 billion, resulting in a value-invest ratio of about 1.65. Conclusions: Our study shows that the benefits of the use of lenalidomide in the treatment of MM extend beyond clinical advantages. Due to longer PFS and OS, this treatment also yields positive economic and societal effects.